FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2523525061> ?p ?o ?g. }

• W2523525061 endingPage "7545" @default.
• W2523525061 startingPage "7545" @default.
• W2523525061 abstract "7545 Background: This study was prospectively performed to compare 18F-FLT and 18F-FDG PET for early prediction of response to erlotinib therapy in patients with non-small cell lung cancer (NSCLC). Methods: The patients with histologically proven NSCLC with stage IV or stage IIIB with malignant pleural effusion were eligible. Both 18F-FLT and 18F-FDG PET were performed before and 6 or 7 days after start of erlotinib (150 mg/d) therapy. The maximum standardized uptake value (SUVmax) of primary tumor and the % change of SUVmax after therapy were obtained. After 6 weeks of therapy, the responses were assessed by clinical follow-up and chest CT using RECIST criteria. Results: Among 23 patients who were enrolled, we analyzed 20 patients for whom we had complete data. After 6 weeks of therapy, there were partial response in 6, stable disease in one and progressive disease in 13. The pretherapy SUVmax of primary tumor were not significantly different between responders and non-responders in 18F-FLT (6.2 ± 1.4 vs 6.5 ± 2.1, p = 0.765) and 18F-FDG PET (14.1 ± 6.2 vs 12.7 ± 4.6, p = 0.565). On day 6 ∼ 7 after therapy, the %changes of SUVmax were significantly different between responders and non-responders in 18F-FLT (-38.7 ± 3.4% vs 3.9 ± 20.4%, p < 0.001) and 18F-FDG PET (-38.0 ± 16.5% vs 0.1 ± 14.1%, p = 0.001). In receiver operating characteristic curve analysis, areas under the curve of 18F-FLT and 18F-FDG PET were not significantly different (1.000 vs 0.976, p = 0.398). The sensitity, specificity, positive and negative predictive values of % change of SUVmax were all 100.0% in 18F-FLT PET (cut-off value, < -34.6%), and 92.9%, 100%, 100%, 85.7% in 18F-FDG PET (cut-off value, < -20.3%), respectively. The time to progression was significantly longer in medical responders than non-responders. (p < 0.001). Conclusions: The %chnage of SUVmax of primary tumor obtained by 18F-FLT or 18F-FDG PET after 6 ∼7 days therapy of erlotonib was a promising predictive variable of the response. The predictive performance of 18F-FLT and 18F-FDG PET are comparable at early after erlotinib therapy in patients with NSCLC. No significant financial relationships to disclose." @default.
• W2523525061 created "2016-09-30" @default.
• W2523525061 creator A5016288301 @default.
• W2523525061 creator A5021590837 @default.
• W2523525061 creator A5024391055 @default.
• W2523525061 creator A5026508160 @default.
• W2523525061 creator A5031498423 @default.
• W2523525061 creator A5037504599 @default.
• W2523525061 creator A5040739505 @default.
• W2523525061 creator A5070243507 @default.
• W2523525061 creator A5085834012 @default.
• W2523525061 date "2010-05-20" @default.
• W2523525061 modified "2023-09-26" @default.
• W2523525061 title "The usefulness of 18f-fluorothymidine (FLT) and 18f-FDG PET for early prediction of response to erlotinib therapy in patients with advanced non-small cell lung cancer." @default.
• W2523525061 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.7545" @default.
• W2523525061 hasPublicationYear "2010" @default.
• W2523525061 type Work @default.
• W2523525061 sameAs 2523525061 @default.
• W2523525061 citedByCount "1" @default.
• W2523525061 countsByYear W25235250612012 @default.
• W2523525061 crossrefType "journal-article" @default.
• W2523525061 hasAuthorship W2523525061A5016288301 @default.
• W2523525061 hasAuthorship W2523525061A5021590837 @default.
• W2523525061 hasAuthorship W2523525061A5024391055 @default.
• W2523525061 hasAuthorship W2523525061A5026508160 @default.
• W2523525061 hasAuthorship W2523525061A5031498423 @default.
• W2523525061 hasAuthorship W2523525061A5037504599 @default.
• W2523525061 hasAuthorship W2523525061A5040739505 @default.
• W2523525061 hasAuthorship W2523525061A5070243507 @default.
• W2523525061 hasAuthorship W2523525061A5085834012 @default.
• W2523525061 hasConcept C121608353 @default.
• W2523525061 hasConcept C126322002 @default.
• W2523525061 hasConcept C143998085 @default.
• W2523525061 hasConcept C146357865 @default.
• W2523525061 hasConcept C151730666 @default.
• W2523525061 hasConcept C199374082 @default.
• W2523525061 hasConcept C2775842073 @default.
• W2523525061 hasConcept C2776256026 @default.
• W2523525061 hasConcept C2776694085 @default.
• W2523525061 hasConcept C2778087573 @default.
• W2523525061 hasConcept C2778822529 @default.
• W2523525061 hasConcept C2779438470 @default.
• W2523525061 hasConcept C2779634585 @default.
• W2523525061 hasConcept C2989005 @default.
• W2523525061 hasConcept C58471807 @default.
• W2523525061 hasConcept C71924100 @default.
• W2523525061 hasConcept C76318530 @default.
• W2523525061 hasConcept C86803240 @default.
• W2523525061 hasConceptScore W2523525061C121608353 @default.
• W2523525061 hasConceptScore W2523525061C126322002 @default.
• W2523525061 hasConceptScore W2523525061C143998085 @default.
• W2523525061 hasConceptScore W2523525061C146357865 @default.
• W2523525061 hasConceptScore W2523525061C151730666 @default.
• W2523525061 hasConceptScore W2523525061C199374082 @default.
• W2523525061 hasConceptScore W2523525061C2775842073 @default.
• W2523525061 hasConceptScore W2523525061C2776256026 @default.
• W2523525061 hasConceptScore W2523525061C2776694085 @default.
• W2523525061 hasConceptScore W2523525061C2778087573 @default.
• W2523525061 hasConceptScore W2523525061C2778822529 @default.
• W2523525061 hasConceptScore W2523525061C2779438470 @default.
• W2523525061 hasConceptScore W2523525061C2779634585 @default.
• W2523525061 hasConceptScore W2523525061C2989005 @default.
• W2523525061 hasConceptScore W2523525061C58471807 @default.
• W2523525061 hasConceptScore W2523525061C71924100 @default.
• W2523525061 hasConceptScore W2523525061C76318530 @default.
• W2523525061 hasConceptScore W2523525061C86803240 @default.
• W2523525061 hasIssue "15_suppl" @default.
• W2523525061 hasLocation W25235250611 @default.
• W2523525061 hasOpenAccess W2523525061 @default.
• W2523525061 hasPrimaryLocation W25235250611 @default.
• W2523525061 hasRelatedWork W1967055700 @default.
• W2523525061 hasRelatedWork W2068522448 @default.
• W2523525061 hasRelatedWork W2312476505 @default.
• W2523525061 hasRelatedWork W2523525061 @default.
• W2523525061 hasRelatedWork W2809998966 @default.
• W2523525061 hasRelatedWork W2893990160 @default.
• W2523525061 hasRelatedWork W2912294510 @default.
• W2523525061 hasRelatedWork W2971615759 @default.
• W2523525061 hasRelatedWork W2992895890 @default.
• W2523525061 hasRelatedWork W3134813758 @default.
• W2523525061 hasVolume "28" @default.
• W2523525061 isParatext "false" @default.
• W2523525061 isRetracted "false" @default.
• W2523525061 magId "2523525061" @default.
• W2523525061 workType "article" @default.